No black box warning on record for Xenpozyme

As of the latest FDA labeling reviewed, Xenpozyme (OLIPUDASE ALFA-RPCP) does not carry a black box warning. Standard warnings and precautions still apply — see the full Xenpozyme medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Infusion-Associated Reactions (IARs): If severe IARs occur, discontinue XENPOZYME and initiate appropriate medical treatment. ( 5.2 ) Elevated Transaminases: Assess ALT and AST within one month prior to initiation of XENPOZYME, within 72 hours prior to any infusion during dose escalation, or prior to the next scheduled XENPOZYME infusion upon resuming treatment following

No black box warning on record for Xenpozyme

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Infusion-Associated Reactions (IARs): If severe IARs occur, discontinue XENPOZYME and initiate appropriate medical treatment. ( 5.2 ) Elevated Transaminases: Assess ALT and AST within one month prior to initiation of XENPOZYME, within 72 hours prior to any infusion during dose escalation, or prior to the next scheduled XENPOZYME infusion upon resuming treatment following

Xenpozyme Black Box Warning

No black box warning on record for Xenpozyme

Other warnings & precautions

Xenpozyme Black Box Warning

No black box warning on record for Xenpozyme

Other warnings & precautions